Large B-cell Lymphoma
Dec 15, 2023
Harmony in Treatment: GOLCA (golcadomide) Reveals Favorable Safety Profile and Seamless Integration with R-CHOP for Untreated Aggressive B-Cell Lymphoma
Date of Abstract presentation11th December 2023IndicationsAggressive B-cell lymphoma (a-BCL)Abstract Number4459Abstract typePoster Approximately 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) experience relapse following initial treatment with rituximab, cyclophosphamide, doxorubicin, vincr...
Read More...
Dec 15, 2023
ALLO-647 Integration in Lymphodepletion: Paving the Way for Enduring Responses and Safe CAR T cell Therapy Advancements
Date of Abstract presentation9th December 2023IndicationsRelapsed/Refractory (r/r) Large B-Cell and Follicular LymphomasAbstract Number2095Abstract typePoster Despite the rising clinical fascination with autologous CAR T-cell therapies for hematologic malignancies and their noteworthy achievements, persistent ch...
Read More...
Dec 15, 2023
Golcadomide and Rituximab Combo Unveils Promising Efficacy in Heavily Pretreated Relapsed/Refractory DLBCL
Date of Abstract presentation11th December 2023IndicationsDiffuse large B-cell lymphoma (DLBCL)Abstract Number4496Abstract typePoster Diffuse large B-cell lymphoma (DLBCL) stands as a swiftly progressing and aggressive ailment, representing the predominant type of non-Hodgkin lymphoma (NHL) and encompassing one-...
Read More...
Dec 12, 2023
Liso-cel (lisocabtagene maraleucel) Shines in Second-Line, Yielding Long-Lasting Complete Responses for Non-Transplant Eligible LBCL Patients
Date of Abstract presentation9th December 2023IndicationsLarge B-cell lymphoma (LBCL)Abstract Number105Abstract typeOral For those patients with large B-cell lymphoma (LBCL) who remain uncured following initial treatment, the conventional approach for second-line therapy has been the utilization of high-dose che...
Read More...
Nov 22, 2022
FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL
Merck to Acquire Imago BioSciences, Inc. for USD 1.35 Billion While its rumored acquisition of Seagen has yet to materialize, Merck & Co has continued to bolster its pipeline with smaller transactions, the most recent of which was a USD 1.35 billion agreement to acquire Imago BioSciences and its bomedemstat ...
Read More...
Jun 28, 2022
Ipsen to Buy Epizyme; BioMarin’s Gene Therapy for Hemophilia; AbbVie’s Qulipta for Chronic Migraine; FDA Approves Breyanzi for R/R LBCL; NDA Filed for Elacestrant in ER+/HER2- Breast Cancer; EU Approval to Enhertu for Breast Cancer; FDA Approves Novartis’ BRAF-positive Tumor Combination; GSK’s Hepatitis B Vaccine, Bepirovirsen
Ipsen to Buy Biopharmaceutical Company Epizyme for USD 247 Million The restructuring of French manufacturer Ipsen has progressed with a takeover agreement for US competitor Epizyme and its cancer drug Tazverik in a deal for slightly less than USD 250 million. Ipsen is proposing USD 1.45 per share for Epizyme, va...
Read More...
Feb 22, 2022
Sandoz’s Generic Revlimid; Agios’ Pyrukynd; Organon Announces 4Q & Full-year Earnings Report; BMS’ CAR-T Drug Breyanzi; Sanofi & Regeneron’s Dupixent Trial; AZ & Daiichi’s Drug Enhertu; Bayer’s Drug Kerendia; Lilly Releases Mirikizumab Data
Sandoz Launches generic Revlimid in 19 European Countries, Bringing a Flood of Competition to BMS' Megablockbuster Since Bristol Myers Squibb acquired Celgene and its megablockbuster Revlimid, the company has been bracing for the day when the multiple myeloma superstar would face generic competition. Sandoz, a s...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
